COMUNICARE SOLUTIONS

Their core work

Comunicare Solutions is a Belgian health-tech SME specializing in AI-powered medical imaging analysis and clinical decision support systems. Their work focuses on applying deep learning to computed tomography (CT) scans for diagnosis and prognosis, particularly in lung cancer and pandemic response contexts. They contribute software and AI components to large European research consortia tackling precision medicine and patient-centered care.

What they specialise in

How they've shifted over time

Comunicare Solutions entered H2020 in 2017 through cancer treatment research, contributing to the IMMUNOSABR clinical trial on lung cancer immunotherapy as a third party. By 2020, they pivoted decisively toward AI and deep learning applied to medical imaging, joining two projects (icovid and DRAGON) focused on CT-based diagnosis and pandemic decision support. This shift from clinical trial support to AI-driven diagnostics suggests the company built or acquired significant machine learning capabilities between 2017 and 2020.

Moving firmly toward AI/deep learning applications in healthcare, particularly CT-based diagnostics and precision medicine decision support — expect them to pursue further medical AI projects.

How they like to work

Comunicare Solutions operates exclusively as a contributing partner or third party — they have never coordinated an H2020 project. With 43 unique consortium partners across 8 countries from just 3 projects, they participate in large, multi-national consortia rather than small focused teams. This suggests they provide a specialized technical component (likely AI/software) within larger clinical or research efforts, making them a low-overhead partner to bring into a consortium.

Despite only 3 projects, they have collaborated with 43 partners across 8 countries, indicating involvement in large health research consortia. Their network is concentrated in the European health and clinical research ecosystem.

What sets them apart

Comunicare Solutions bridges the gap between clinical medicine and AI engineering — a rare combination for a small Belgian SME. Their trajectory from cancer immunotherapy trials to AI-based CT diagnostics means they understand both the clinical context and the technical implementation, which is valuable for consortia that need AI partners who genuinely grasp medical workflows. Their DRAGON project funding (nearly EUR 1M) shows they can win substantial roles despite being a small company.

Highlights from their portfolio

• DRAGON
  Their largest funded role (EUR 996,595) — an ambitious project applying AI and deep learning to pandemic-era precision medicine and patient empowerment.
• icovid
  A rapid-response COVID-19 project using AI to analyze chest CT scans, demonstrating the company's ability to deploy imaging AI for urgent public health needs.